BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26461002)

  • 21. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan.
    Aerts HJ; van Baardwijk AA; Petit SF; Offermann C; Loon Jv; Houben R; Dingemans AM; Wanders R; Boersma L; Borger J; Bootsma G; Geraedts W; Pitz C; Simons J; Wouters BG; Oellers M; Lambin P; Bosmans G; Dekker AL; De Ruysscher D
    Radiother Oncol; 2009 Jun; 91(3):386-92. PubMed ID: 19329207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer.
    Chen PJ; Yap WK; Chang YC; Tseng CK; Chao YK; Hsieh JC; Pai PC; Lee CH; Yang CK; Ho AT; Hung TM
    BMC Cancer; 2020 Jun; 20(1):545. PubMed ID: 32522275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
    Kong FM; Ten Haken RK; Schipper M; Frey KA; Hayman J; Gross M; Ramnath N; Hassan KA; Matuszak M; Ritter T; Bi N; Wang W; Orringer M; Cease KB; Lawrence TS; Kalemkerian GP
    JAMA Oncol; 2017 Oct; 3(10):1358-1365. PubMed ID: 28570742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy.
    van Diessen JN; Chen C; van den Heuvel MM; Belderbos JS; Sonke JJ
    Radiother Oncol; 2016 Mar; 118(3):447-52. PubMed ID: 26900092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
    Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
    Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
    [TBL] [Abstract][Full Text] [Related]  

  • 32.  ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose.
    Massaccesi M; Calcagni ML; Spitilli MG; Cocciolillo F; Pelligrò F; Bonomo L; Valentini V; Giordano A
    Radiat Oncol; 2012 Jul; 7():106. PubMed ID: 22781363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
    J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.
    Bahce I; Vos CG; Dickhoff C; Hartemink KJ; Dahele M; Smit EF; Boellaard R; Hoekstra OS; Thunnissen E
    Lung Cancer; 2014 Aug; 85(2):205-12. PubMed ID: 24854401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial.
    Miller R; Santangelo T; Forghani-Arani F; Rusthoven C; Chen Y; Castillo E; Castillo R; Guerrero T; Vinogradskiy Y
    Radiother Oncol; 2022 Jun; 171():22-24. PubMed ID: 35413391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic importance of
    Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation?
    Rodríguez N; Sanz X; Trampal C; Foro P; Reig A; Lacruz M; Membrive I; Lozano J; Quera J; Algara M
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):659-66. PubMed ID: 20133071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
    Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
    Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.